LLY vs BIIB
By Alex · Tickerpine
Eli Lilly and Company vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BIIB |
|---|---|---|
| Price | $1,183.46 | $227.60 |
| Market cap | $1.06T | $33.63B |
| P/E ratio | 39.7 | 40.7 |
| ROE | 102.29% | 4.58% |
| Profit margin | 33.53% | 8.32% |
| Revenue growth | 47.70% | 3.40% |
| Dividend yield | 0.58% | — |
| Beta | 0.50 | 0.17 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BIIB in plain English
- LLY is the bigger company — about 31.4× the market cap of BIIB.
- LLY is cheaper on earnings (P/E 39.7 vs 40.7).
- LLY earns a higher return on equity (102% vs 5%).
- LLY is growing revenue faster (48% vs 3%).
- LLY pays a dividend (0.58%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.